This paper is only available as a PDF. To read, Please Download here.
To assess changes in the proportion of Texas residents, gestational age at time of abortion, and rates of second-trimester abortion, at a university-affiliated abortion clinic in Colorado after Texas passed Senate Bill 8 (SB8), which prohibits abortions >6 weeks’ gestation.
We focused on all patients obtaining an abortion ≤22 weeks’ gestation at a university-affiliated clinic between January 2018 and mid-April 2022. We created two time periods: before SB8 (January 2018–August 2021) and after SB8 (September 2021–April 2022). We compared the proportion of Texas residents obtaining care and gestational age categories before and after SB8 using chi-square tests. We determined the adjusted odds of a second-trimester abortion (≥13 weeks) after SB8 using logistic regression models adjusted for gravida, parity, age, and the proportion of Texas residents.
We assessed 4,358 abortions; 3,630 before and 728 after SB8. After SB8, the proportion of patients who were Texas residents increased from 1% to 17%, p<0.001. Among all patients, abortions ≥15 weeks increased from 11% to 21%, p<0.01, and surgical abortions at 6–10 weeks decreased from 46% to 33%, p<0.001. There was no change in abortions at 11–14 weeks. The proportion of second-trimester abortions increased from 17% to 27%, p<0.001 and the odds nearly doubled after SB8 (aOR1.9, 95% CI, 1.6–2.3). Although higher among Texas residents (aOR, 2.6, 95% CI,1.1–6.9), the odds of a second-trimester abortion also increased among Colorado residents (aOR,1.8, 95% CI, 1.4–2.2).
Post-Roe abortion bans will likely delay care not only for people forced to seek care out of state, but for residents of states maintaining abortion access.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2022 Published by Elsevier Inc.